CS
CTXR icon

Credit Suisse’s Citius Pharmaceuticals CTXR Stock Holding History

Credit Suisse’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-631
Closed -$24K – 3747
2021
Q4 		$24K Buy
+631
New +$28.6K ﹤0.01% 4443
2021
Q3 		– Sell
-5,527
Closed -$481K – 4416
2021
Q2 		$481K Buy
+5,527
New +$332K ﹤0.01% 3869

Other funds holding CTXR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Credit Suisse's CTXR Position: Q1 2022 in Review

Credit Suisse sold out of Citius Pharmaceuticals (CTXR) in Q1 2022, closing a stake of 631 shares — an estimated $24K sold.

Credit Suisse first reported a position in CTXR in Q2 2021 and held it in 2 quarters. The position peaked at $481K in Q2 2021. 76 funds tracked by Wall St. Rank hold CTXR as of Q1 2022.

  • Credit Suisse reported no remaining Citius Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Credit Suisse sold 631 Citius Pharmaceuticals shares in Q1 2022, an estimated $24K.
  • Credit Suisse first reported a position in Citius Pharmaceuticals in Q2 2021 and held it in 2 quarters.
  • Credit Suisse's Citius Pharmaceuticals position peaked at $481K in Q2 2021.
  • 76 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q1 2022.

Based on Credit Suisse's 13F filing for Q1 2022, filed 16 May 2022.